Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells.
about
Novel Insights into the Roles of Rho Kinase in CancerRho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunitiesROCK1 as a novel prognostic marker in vulvar cancerOverexpression of ROCK1 and ROCK2 inhibits human laryngeal squamous cell carcinoma.ROCK inhibitor Y-27632 inhibits the growth, migration, and invasion of Tca8113 and CAL-27 cells in tongue squamous cell carcinoma.Parathyroid hormone regulation of hypoxia-inducible factor signaling in osteoblastic cells.FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.Inhibitors of Rho kinase (ROCK) signaling revert the malignant phenotype of breast cancer cells in 3D contextRhoE/ROCK2 regulates chemoresistance through NF-κB/IL-6/ STAT3 signaling in hepatocellular carcinoma.Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.Combination treatment with fasudil and clioquinol produces synergistic anti-tumor effects in U87 glioblastoma cells by activating apoptosis and autophagy.Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.Long non-coding RNA NEAT1 promoted ovarian cancer cells' metastasis via regulating of miR-382-3p/ROCK1 axial.
P2860
Q26771368-29552C6E-8FCE-449B-9282-5A288FEC5193Q26778344-401418AA-A486-4426-ACEC-0FB8CCD9155AQ34515462-F31FBF07-3851-48B0-A8F1-FCD89C6560A3Q35145294-F8890A52-AEE9-46A8-8D3C-17E2F71C3CECQ35807790-FA542363-AA6C-4308-878C-B5E9DC94BCB3Q36269239-CD7331F5-A28B-435D-B02A-4106BB32B016Q36413873-4245F832-3291-4B1F-AB7D-7B4D8E4A307FQ37362471-6AB82379-3D46-42EC-8D3C-5678388E25BEQ39541068-06319EB6-D65C-4691-BF62-A36A45F946C8Q41484257-5E40C85A-9C08-4482-8A0C-93B034865E34Q41916031-CEED8A72-33BF-4931-AD72-FBC6D779485FQ44447816-EEECB7CD-6090-43FE-AC69-530EF2C943D7Q50130110-34AFEE81-682C-48A4-B427-0E352C781036Q54978459-51420A74-5CA3-44EE-8C74-2C3A7D281587
P2860
Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Inhibition of the Rho/ROCK pat ...... in human ovarian cancer cells.
@en
Inhibition of the Rho/ROCK pat ...... in human ovarian cancer cells.
@nl
type
label
Inhibition of the Rho/ROCK pat ...... in human ovarian cancer cells.
@en
Inhibition of the Rho/ROCK pat ...... in human ovarian cancer cells.
@nl
prefLabel
Inhibition of the Rho/ROCK pat ...... in human ovarian cancer cells.
@en
Inhibition of the Rho/ROCK pat ...... in human ovarian cancer cells.
@nl
P2093
P2860
P356
P1476
Inhibition of the Rho/ROCK pat ...... in human ovarian cancer cells.
@en
P2093
Hirohisa Kurachi
Kazuhiro Takahashi
Mitsuyoshi Amita
Noriko Henmi
Tae Shibuya
Toshifumi Takahashi
Tsuyoshi Ohta
P2860
P356
10.4161/CBT.13.1.18440
P577
2012-01-01T00:00:00Z